Cedars-Sinai Scientist Finds Malignancy Gene In Tumor Cells

October 30, 1998

LOS ANGELES -- A scientist at Cedars-Sinai Medical Center has discovered a gene that exists in malignant tumors of the brain, liver, breast, colon, kidney, and reproductive organs, but not in healthy adults, stirring hopes that a vital key to cancer development and progression may have been unmasked.

Julia Y. Ljubimova, M.D., Ph.D., a cancer researcher in the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, announced the discovery of a novel human malignancy-associated gene (MAG) in the October issue of Cancer Research, the Philadelphia-based journal of the American Association for Cancer Research.

"We feel that this gene may 'turn on' the process of malignancy," said Dr. Ljubimova (pronounced "Lou-bee-mo-va"), a native of Russia who is a member of Dr. Keith Black's neurosurgical research team. Once the newly-found gene has been completely sequenced, a process that could be completed in three months, work will begin on genetically engineering a method of blocking the gene's expression. Herein may lie its greatest clinical significance, said Dr. Ljubimova. "Most patients die from metastasis or invasion," she said. "If, using antisense technology, the gene could be deactivated, a tumor cell's blueprint for rampant growth might be destroyed, and the cancer stopped before it spread."

"The discovery of the MAG gene was serendipitous," Dr. Ljubimova explained, "the result of looking at expression of another gene (c-met proto-oncogene) in normal and cancerous human liver tissues. An extra polymerase chain reaction (PCR) band kept appearing in specimens from livers from patients with advanced cirrhosis or liver cancer. Further exploration led to the conclusion that it was a gene associated with malignancy. In her paper, Dr. Ljubimova wrote, "Analysis of 30 liver and five brain disease cases for MAG expression has indicated its potential importance in liver and brain neoplasia. The absence of MAG expression in different normal tissues and its presence in various malignancies supports the hypothesis that this novel gene may play an important role in the process of malignant transformation."

The MAG gene is not the only example of a genetic signal present in more than one type of cancer. Expression of prostate specific antigen, for example, is observed in both prostate and breast cancer.

MAG, however, appears to be a common element in a wide variety of cancers. It was seen in 90 percent of 51 premalignant and malignant tissue samples, including glioblastomas and carcinomas of the lung, breast, colon, kidney, prostate, endometrium, ovary, and uterus. Intriguingly, expression of MAG messenger RNA (mRNA) was also found in fetal brain and liver tissue. Under normal circumstances, the gene is no longer seen once organs mature, and no evidence of its telltale polymerase chain reaction band could be found in any tissue from a healthy adult. Expression of this gene was supported by other molecular biological methods.

Another so-called oncofetal gene is alpha-fetoprotein, which is found in embryonic liver tissue and in liver cancer (hepatocellular carcinoma), but not in normal adult liver cells. It is believed that these genes give commands for rapid growth that are appropriate in a developing fetus, but dangerous in an adult whose cells should divide in a slow and orderly fashion.

Expression of the MAG gene appeared in tissue samples of patients with advanced cirrhosis of the liver, a condition that often precedes liver cancer, but not in samples from patients with a liver disease that is not associated with malignancy, fulminant hepatic failure. This suggests the MAG gene is not just a marker for disease, but an early player in the transformation of cells from normal to malignant.

Dr. Ljubimova noted that the Cedars-Sinai work was an interdisciplinary effort between the Maxine Dunitz Neurosurgical Institute, led by Dr. Keith Black; the Department of Surgery, led by Dr. Achilles A. Demetriou; and the Department of Pathology, led by Dr. Stephen A. Geller.
-end-
Dr. Ljubimova is available for interviews. To arrange, please contact Roberta Nichols
at (310) 855-4767.

Media Contact: Roberta Nichols or Anita Roark (310) 855-4767
-end-


Cedars-Sinai Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.